NK cells complexed with bispecific antibody yield high response rates in patients with lymphoma
HOUSTON ― A novel cell therapy approach using cord blood-derived natural killer (NK) cells pre-complexed with AFM13, or acimtamig, a CD30/CD16A bispecific antibody, was safe and generated strong response rates for patients with refractory CD30-positive lymphomas, according to a new study from Â鶹ӳ» MD Anderson Cancer Center.
Results from the Phase I trial, published today in Nature Medicine, demonstrated an overall...
ASH: Triplet combination regimens demonstrate high response rates in multiple leukemias
ABSTRACTS: 216, 219, 1011Â Â
SAN DIEGO ― Three clinical trials led by researchers from Â鶹ӳ» MD Anderson...
ASH: Monoclonal antibody therapy improves survival in cancer-associated hyper-inflammatory disorder
ABSTRACT: 805
SAN DIEGO – Adult patients with newly diagnosed malignancy-associated hemophagocytic lymphohistiocytosis (mHLH) – a rare...
Novel CAR T cell therapy obe-cel demonstrates high response rates in adult patients with advanced B-cell ALL
Patients with relapsed or refractory CD19-positive B-cell acute lymphoblastic leukemia (ALL) who were treated with the novel anti-CD19 chimeric antigen receptor (CAR) T cell therapy, obecabtagene autoleucel (obe-cel), experienced high response rates and most did not need a subsequent stem cell transplant (SCT), according to results from the Phase Ib/II FELIX trial co-led by researchers at Â鶹ӳ» MD Anderson Cancer Center...
MD Anderson launches Institute for Cell Therapy Discovery & Innovation to deliver transformational new therapies
Â鶹ӳ» MD Anderson Cancer Center today announced the launch of its Institute for Cell Therapy Discovery & Innovation,...
Novel triplet regimen yields promising response in advanced-phase chronic myeloid leukemia
According to researchers at Â鶹ӳ» MD Anderson Cancer Center, 80% of patients with previously untreated or relapsed/refractory...
ESMO: Combination therapy reduced agitated delirium in patients with advanced cancers
ABSTRACT: 1476O
BARCELONA, Spain ― Treatment with a combination of haloperidol and lorazepam reduced symptoms of agitated delirium,...
NK cells expressing interleukin-21 show promising antitumor activity in glioblastoma cells
Natural killer (NK) cells engineered to express interleukin-21 (IL-21) demonstrated sustained antitumor activity against glioblastoma stem...
CAR NK cells with CD28 costimulation improved cell persistence and antitumor activity
Adding CD28 costimulation to cord blood-derived chimeric antigen receptor (CAR) natural killer (NK) cells targeting CD70+ cancers significantly...
ASCO: Novel CAR T therapy and shorter targeted therapy durations show promise for patients with leukemia
ABSTRACTS: 6504, 6507
Researchers from Â鶹ӳ» MD Anderson Cancer Center presented positive clinical results from two...